# MELT-MM (NCT06645678)

> Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06645678
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: YOUNGIL KOH
- Conditions: Relapsed Refractory Multiple Myeloma (RRMM)
- Interventions: Elranatamab; Mezigdomide; Dexamethasone
- Enrollment: 75
- Primary outcome: Overall response rate (ORR)

## Commentary we found

- YouTube: 4
- X threads: 4
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=melt-mm-nct06645678

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06645678", "email": "<work email>"}; the inbox owner confirms by the emailed link.